Presentation is loading. Please wait.

Presentation is loading. Please wait.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Published byUrsula Murphy Modified over 5 years ago

Similar presentations

Presentation on theme: "Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol."— Presentation transcript:

1 Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol between exenatide once weekly and comparators. Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol between exenatide once weekly and comparators. Susan LaRue et al. Diabetes Spectr 2013;26:46-52 ©2013 by American Diabetes Association

Download ppt "Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol."

Similar presentations

Pancreas, Insulin & Diabetes In One Day 2015.

Pancreas, Insulin & Diabetes In One Day 2015.
Non-diabetes 64.7% Diabetes 35.3% Diagnosed diabetes 5.6% Pre-diabetes 26.0% Undiagnosed diabetes 2.8% Age-adjusted diabetes prevalence among Alaska adults,

Non-diabetes 64.7% Diabetes 35.3% Diagnosed diabetes 5.6% Pre-diabetes 26.0% Undiagnosed diabetes 2.8% Age-adjusted diabetes prevalence among Alaska adults,
Diabetes and High Blood Pressure Are Like Twins. Ignoring Your High Blood Pressure.

Diabetes and High Blood Pressure Are Like Twins. Ignoring Your High Blood Pressure.
PICK A CARD When the picture you hold in your hand is displayed you will be asked a question Ready set go…….

PICK A CARD When the picture you hold in your hand is displayed you will be asked a question Ready set go…….
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.
PICK A CARD The wheel will spin and whoever has that card will be asked a question about the subject pictured on the card Ready set go…….

PICK A CARD The wheel will spin and whoever has that card will be asked a question about the subject pictured on the card Ready set go…….
Lacto-ovo vegetarian group

Lacto-ovo vegetarian group
Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes
Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’

Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’
Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic
Change (with 95% CI) in outcomes by duration of type 2 diabetes

Change (with 95% CI) in outcomes by duration of type 2 diabetes
Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.
Figure 5 Risk factor control in the intensive treatment group

Figure 5 Risk factor control in the intensive treatment group
Joshua A. Bell et al. JACC 2018;72:

Joshua A. Bell et al. JACC 2018;72:
A summary of Lisa and Gerard, the two personas created during this study, including quotes that describe their attitude toward diabetes. A summary of Lisa.

A summary of Lisa and Gerard, the two personas created during this study, including quotes that describe their attitude toward diabetes. A summary of Lisa.
PWD confidence with key diabetes management activities.

PWD confidence with key diabetes management activities.
PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

Similar presentations

Ads by Google